We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

15 hedge funds and large institutions have $677K invested in NeuBase Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more capital invested

Capital invested by funds: $371K → $677K (+$306K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

38% less funds holding

Funds holding: 24 → 15 (-9)

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
15
Holders Change
-9
Holders Change %
-37.5%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
2
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$166K
2
Creative Planning
Creative Planning
Kansas
+$102K
3
MIG
Mariner Investment Group
New York
+$58.3K
4
SSB
Sandy Spring Bank
Maryland
+$861
5
BlackRock
BlackRock
New York
+$48

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$16K
2
WS
Wedbush Securities
California
-$12K
3
Northern Trust
Northern Trust
Illinois
-$11K
4
VF
Virtu Financial
New York
-$11K
5
UBS Group
UBS Group
Switzerland
-$10.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$379K +$166K +3,461 +70%
Creative Planning
2
Creative Planning
Kansas
$104K +$102K +2,138 +1,258%
Vanguard Group
3
Vanguard Group
Pennsylvania
$60K – – –
MIG
4
Mariner Investment Group
New York
$55K +$58.3K +1,220 New
BlackRock
5
BlackRock
New York
$47K +$48 +1 +0.1%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$30K – – –
WAM
7
Wealthspire Advisors (Maryland)
Maryland
$1K – – –
SSB
8
Sandy Spring Bank
Maryland
$1K +$861 +18 New
Citadel Advisors
9
Citadel Advisors
Florida
– -$16K -478 Closed
Northern Trust
10
Northern Trust
Illinois
– -$11K -339 Closed
WS
11
Wedbush Securities
California
– -$12K -338 Closed
VF
12
Virtu Financial
New York
– -$11K -321 Closed
GBA
13
Garrison Bradford & Associates
New York
– -$9K -253 Closed
UBS Group
14
UBS Group
Switzerland
– -$10.4K -218 -96%
California Public Employees Retirement System
15
California Public Employees Retirement System
California
– -$7K -197 Closed
PP
16
Paloma Partners
Connecticut
– -$7K -191 Closed
LCM
17
Leisure Capital Management
California
– -$5K -145 Closed
Bank of New York Mellon
18
Bank of New York Mellon
New York
– -$3K -84 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$96 -2 -17%

NBSE Hedge Fund Activity: Q1 2019 in Review

15 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2019, worth a combined $677K — up 82% from $371K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NBSE and 2 opened new positions — a net loss of 9 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $166K. The largest seller was Citadel Advisors, exiting entirely with an estimated $16K sold.

  • 15 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2019, down from 24 in Q4 2018.
  • Funds reported $677K of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2019, up 82% quarter-over-quarter.
  • 2 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2019 and 11 closed out, a net change of -9 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $166K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2019 was Citadel Advisors, an estimated $16K sold.

Based on aggregated 13F filings for Q1 2019.